ライフサイエンスコーパス: surviving patient

1 GVHD (n = 86) (the status was uncertain in 1 surviving patient).

2 t discharge (home or another hospital, among surviving patients).

3 a longer follow-up (median, 47.6 months for surviving patients).

4 e and 266 were reassessed at 4 years (94% of surviving patients).

5 provement of motor function over time in the surviving patient.

6 was 3.3 years (range, 0.6 to 4.4 years) for surviving patients.

7 -up of 43 months (range, 34-54) for the four surviving patients.

8 tion of chronic graft-versus-host disease in surviving patients.

9 , and the median follow-up was 57 months for surviving patients.

10 ow-up of 59 months (range, 27-78 months) for surviving patients.

11 32 months for all patients and 42 months for surviving patients.

12 hs with a median follow-up of 115 months for surviving patients.

13 of clinical visit or telephone interview for surviving patients.

14 nths (range, 1-264 months) and 51 months for surviving patients.

15 linical status was ascertained in 167 of 171 surviving patients.

16 to evaluate the relative risk of relapse in surviving patients.

17 on nonfatal events was available for 95% of surviving patients.

18 lief and improved quality of life in all the surviving patients.

19 nformation on the current clinical status of surviving patients.

20 No relapse has been seen in surviving patients.

21 follow-up was 10.6 (IQR, 8.0-17.8) years for surviving patients.

22 eyond 1 year, up to 40 months after AORIF in surviving patients.

23 QR) follow-up was 4.01 (2.93-4.92) years for surviving patients.

24 criteria; median follow-up was 51 months for surviving patients.

25 oid donor chimerism was documented in 80% of surviving patients.

26 p was 39.6 months (range, 24.5-69.3) for all surviving patients.

27 and an extremely low percentage of long-term surviving patients.

28 ugs on the risk of clinical deterioration in surviving patients.

29 d donor chimerism was documented in 52 (93%) surviving patients.

30 of IgG responses was significantly higher in surviving patients.

31 wever, 6 months after surgery, only 4 of 243 surviving patients (1.6%) had a persistent language defi

32 Currently, two thirds of the surviving patients (11 of 17) have experienced improveme

33 Of surviving patients, 11% were molecularly positive for th

34 tic stress-related symptoms in relatives and surviving patients 12 months after intensive care unit d

35 Of the 19 surviving patients, 16 (84%) exhibit T-wave inversions,

36 died of hypertrophic cardiomyopathy, and 216 surviving patients (20 percent) had severe, disabling sy

37 ith a median follow-up time of 43 months for surviving patients, 20 patients have had disease progres

38 Of the surviving patients, 20.4% remained on antibiotic therapy

39 Of the 24 surviving patients, 22 (92%) are both dialysis- and insu

40 atients, and the 1-year cohort included 7014 surviving patients (3454 women [49.2%] and 3560 men [50.

41 Of the 12 surviving patients, 5 were discharged home, 4 were disch

42 Among surviving patients, 61% had neurological sequelae.

43 Of evaluable surviving patients, 70% are visually impaired; 10% have

44 Of the surviving patients, 71 had ND outcomes assessed.

45 Of the 10 surviving patients, 8 were tested further for viral repl

46 At present, 22 surviving patients (81%) remain on triple immunosuppress

47 At 1 year, the majority of surviving patients (82.9%) remained MR </=2+ at 1 year,

48 Of the surviving patients, 83.3% and 94.4% reached their pre-CO

49 The majority of surviving patients (84.7%) remained with MR <=2+ and New

50 .5% of patients surviving at 5 1/2 years; in surviving patients, 89% of homografts have continued to

51 ctional analysis was performed on 220 of 239 surviving patients (92%) to determine the late incidence

52 beta-Blockers were used in 16 of 17 surviving patients (94%).

53 Esophageal healing occurred in 43 of 45 surviving patients (96%).

54 All 5 surviving patients achieved complete remission and remai

55 The majority (85.7%) of surviving patients achieved tubular recovery after stopp

56 ort- and long-term health status outcomes of surviving patients after TAVR in the context of an unsel

57 atelet levels returned to baseline in all 26 surviving patients after vancomycin was stopped.

58 The four surviving patients all had functioning allografts 1 year

59 is, with a median follow-up of 52 months for surviving patients and 42 months for all patients.

60 Forty-one percent of surviving patients and 50% of all patients were treated

61 y an extensive echocardiography protocol: in surviving patients and homografts, three valved conduits

62 rthermore, it differed significantly between surviving patients and those who died from COVID-19 (p =

63 aftment was achieved in nearly all evaluable surviving patients and was seen even after unconditioned

64 Five-year follow-up was available in 94% of surviving patients, and 8-year follow-up, in 62%.

65 Eighty-nine percent of surviving patients are currently in New York Heart Assoc

66 All the surviving patients are currently supported by enteral di

67 erval of 5.3 years (range 1 to 18.2), all 28 surviving patients are free of exercise limitation (func

68 All surviving patients are now past the 15-month posttranspl

69 d quality of life are mostly preserved among surviving patients at 5 years, thereby supporting the co

70 overall survival times or the proportion of surviving patients at a prespecified time; (4) health-re

71 In surviving patients, bacilli were not observed with gram'

72 Symptoms of surviving patients become mild, although atopic manifest

73 Surviving patients between 10 and 50 years of age had an

74 All surviving patients, but only slightly more than half of

75 functionally a crossover study in which only surviving patients can cross over in one direction (towa

76 The 4 surviving patients cleared HEV after a median period of

77 was high in this population, the majority of surviving patients continued to report reasonable health

78 At 12 months, six of the seven surviving patients demonstrated stable vector copy numbe

79 The 5 surviving patients developed a mean of 983 host CD3(+) T

80 Deceased and surviving patients did not differ significantly in avera

81 Among surviving patients discharged with a prescription of ant

82 At the time of analysis, 87% of surviving patients do not require enteral feeding suppor

83 ntation existed for 16 abnormalities (29% of surviving patients) during a mean follow-up of 3.2 years

84 e ability to KCH criteria but identified non-surviving patients earlier (4 [3--13] vs 10 [3.5--19.5]

85 In all surviving patients, either stable mixed chimerism or ful

86 In 57 surviving patients, EV71 neurological disease included e

87 In the surviving patients evaluated, >=95% donor myeloid chimer

88 All 6 surviving patients exhibited high-level, stable engraftm

89 Since surviving patients experience severe neurocognitive disa

90 In the 47 surviving patients, follow-up data showed greater postop

91 Among all surviving patients for which World Health Organization s

92 Among surviving patients for whom health status data were avai

93 subset of 31 patients with fatal HPS and 20 surviving patients for whom samples were available withi

94 ion and identification of T cell epitopes in surviving patients from Guinea to the EBOV glycoprotein.

95 bnormalities, but at the end of the trial no surviving patient had any detectable visual deficits rel

96 At 30 days, 11 of 12 surviving patients had an available echocardiogram; mitr

97 (1.7%) had major stroke, and 313 (92.6%) of surviving patients had good functional status (New York

98 Surviving patients had median follow-up of 68 months, an

99 -525 days) following transplantation, all 13 surviving patients had no detectable serum HBV DNA.

100 At last follow-up, 87% of the surviving patients had no evidence of persistent or recu

101 At 2 years, 93.2% of surviving patients had no MR.

102 ts had died, while 50%, 37%, 30%, and 35% of surviving patients had not regained their baseline healt

103 Seven of 32 surviving patients had preoperative shortening fractions

104 after orthotopic liver transplantation, all surviving patients had relief of their pain, distention,

105 At 6 months, all surviving patients had shifted down by at least 1 point

106 m the first week after the onset of HPS, all surviving patients had SNV-specific IgG responses, compa

107 Surviving patients had, on average, large improvements i

108 The surviving patients have an average follow-up of 15 month

109 Surviving patients have excellent performance status and

110 Surviving patients have had no new CGD-related infection

111 Moreover, sepsis-surviving patients have more Treg cells, IL-33 and IL-10

112 All surviving patients have normal hepatic allograft functio

113 Six of seven surviving patients have normal renal allograft function,

114 In 3 surviving patients, IHC of pleural samples demonstrated

115 For the 2 surviving patients, improvement in trilineage hematopoie

116 netic abnormalities have been observed among surviving patients in both arms (2 of 14 ATG versus 1 of

117 assumed to be similar to that of the longest surviving patients in the control group.

118 year, 16 of 55 (29.1%) and 23 of 36 (63.9%) surviving patients in the early and delayed groups, resp

119 Sera from surviving patients induced dendritic cell death through

120 Median follow-up for surviving patients is 10.8 years.

121 The median age of surviving patients is 7 years.

122 ive regimen was well tolerated, and in the 9 surviving patients it provided durable engraftment and w

123 c and clinical follow-up was obtained for 36 surviving patients (mean = 8 months; range: 1 week-5 yea

124 pre-TAVR through 5 years of follow-up among surviving patients (mean change from baseline, 14.3 poin

125 For surviving patients, mean SAPS II was 19.6 +/- 7.1 (range

126 For the 466 surviving patients, median follow-up was 32.4 months; me

127 follow-up of 57.7 months (IQR 56.7-59.2) in surviving patients, median overall survival was 32.7 mon

128 follow-up of 11.9 years (range 9.7-14.5 for surviving patients), men assigned immediate ADT had a si

129 Plasma samples from surviving and non-surviving patients (N = 15/group) were taken at day 1 an

130 er in nonsurviving patients (n = 22) than in surviving patients (n = 20) at all time points.

131 Fifty-seven percent of the surviving patients needed caregiver assistance at 1 yr o

132 7.9 years (range, 0.3 to 10.1 years) for 355 surviving patients, no differences were observed in OS (

133 At a median follow-up of surviving patients of 12.4 years, transformation to acti

134 t follow-up with a median follow-up of these surviving patients of 1430 days.

135 ts were enrolled, with a median follow-up of surviving patients of 3.8 years (3-year EFS for all pati

136 With a median follow-up time for surviving patients of 69 months, 20 patients developed t

137 Of eight surviving patients, only two continue to receive intrave

138 Outcomes were assessed via interviews with surviving patients or their surrogates at 6 months.

139 135 65 min in dead patients vs. 76 32 min in surviving patients; p = 0.0005).

140 iod of 5.6 years was assessed among all 1691 surviving patients (phase 1) and subsequently among 854

141 related symptom score after 12 months in the surviving patients (prediary 34.6 +/- 15.9, diary 21 +/-

142 a median follow-up duration of 24 months for surviving patients (range, 3 to 131 months), 112 of 289

143 Both surviving patients received uncontrolled treatment with

144 ing longer with aggressive PT-ReRT; however, surviving patients remain at risk of early and late comp

145 All surviving patients remain in New York Heart Association

146 with immune reconstitution therapy; however, surviving patients remain severely debilitated.

147 Surviving patients remained under follow-up until the en

148 Caregivers of surviving patients reported improved symptoms related to

149 Four of the 6 surviving patients required maintenance low-dose cortico

150 All surviving patients returned to a normal or compensated z

151 Surviving patients showed durable engraftment of donor-d

152 Biopsies of grafted thymus in the surviving patients showed normal morphologic features an

153 Furthermore, one third of surviving patients still have active cancers from which

154 The small population of surviving patients suffer extensive brain damage that re

155 are highly toxic to the developing brain and surviving patients suffer from lifelong side effects.

156 For surviving patients sulfonylurea drug use is not associat

157 sed between 1961 and March 1992, 77 (6.6% of surviving patients tested thus far) have evidence of HCV

158 dian lactate was significantly higher in non-surviving patients than in survivors both in the early s

159 With a median follow-up of 46 months for surviving patients, the 5-year probability of chronic GV

160 Among 62 surviving patients, the 5-year rates for locoregional fa

161 Among 57 surviving patients, the age range was 0.3 to 5.2 years (

162 With a median follow-up of 26.3 months among surviving patients, the cumulative incidence of chronic

163 With a median follow-up of 38 months in surviving patients, the estimated overall survival at 5

164 With a median follow-up of 15 months in surviving patients, the incidence of total grade 3+ toxi

165 Among surviving patients, the KCCQ overall summary score incre

166 Among the surviving patients, the long-term annual MACE rate and t

167 Among surviving patients, the mean (+/-SD) 2-year LVESVI was 5

168 median follow-up time of 79.5 months for all surviving patients, the median OS had not been reached f

169 With a minimum follow-up of 19 months in surviving patients, the median survival and 1-year survi

170 In the surviving patients there was no difference in T-cell rec

171 IgG antibody was detectable in surviving patients through about 2 years after onset, th

172 All surviving patients transplanted for NASH at the authors'

173 In addition, psychomotor development in surviving patients treated with betaine was normal in al

174 At 2 years posttreatment, 1 of the 11 surviving patients treated with gene therapy (9%) requir

175 The median follow-up time of surviving patients was 102 months.

176 The median follow-up among surviving patients was 106 months.

177 The median follow-up among the surviving patients was 13 years.

178 Median follow-up for surviving patients was 135 months.

179 Median follow-up for surviving patients was 152 months.

180 The median follow-up duration of surviving patients was 2.6 years (range, 1.0 to 11.7).

181 The median follow-up time for surviving patients was 22 months (95% CI, 16.6 to 39.1 m

182 Median follow-up of surviving patients was 22 months.

183 Median follow-up for surviving patients was 28 months (range, 16 to 81 months

184 Mean follow-up of surviving patients was 28 months (range, 3-71 months).

185 The median follow-up in surviving patients was 29.5 months.

186 Median follow-up for surviving patients was 32.5 months (IQR 29.8-34.1).

187 The median follow-up of surviving patients was 36 months (interquartile range, 3

188 Median follow-up time for 92 (52%) surviving patients was 37 (mean, 0.5-192) months.

189 The median follow-up for surviving patients was 4 years.

190 chemoradiotherapy), and median follow-up of surviving patients was 4 years.

191 The median follow-up period of surviving patients was 4.1 years.

192 The median follow-up of surviving patients was 40 months, with 23 patients survi

193 Median follow-up for surviving patients was 43 months.

194 At 1 year, the mean LVESVI among surviving patients was 46.1+/-22.4 ml per square meter o

195 Median follow-up of surviving patients was 47 months (range 0-84).

196 Median follow-up for surviving patients was 47 months.

197 December 15, 2015, median follow-up for 263 surviving patients was 47.4 months (range, 0-110.7 month

198 The median follow-up after BMT for surviving patients was 5.1 years (range, 1 to 13.8 years

199 At 12 months, the mean LVESVI among surviving patients was 54.6+/-25.0 ml per square meter o

200 The median length of follow-up in surviving patients was 58 months (range, 10 to 124).

201 The median follow-up of surviving patients was 6.3 months (range, 2.2-12.5 month

202 The median follow-up time for 228 surviving patients was 6.6 years.

203 The median follow-up of the 79 surviving patients was 6.8 years.

204 Median follow-up of surviving patients was 8.2 years for surgery only (range

205 Median follow-up for surviving patients was 8.3 years.

206 Median follow-up for surviving patients was 8.8 years.

207 Worsening of symptom scores in surviving patients was consistently more common in the e

208 At latest follow-up, disease of 28 of 30 surviving patients was in disease-free remission with me

209 The health status of surviving patients was quantified with the use of the 36

210 All surviving patients weaned-off total parenteral nutrition

211 aspartate aminotransferase levels in the 154 surviving patients were 0.5 mg/dL and 34 international u

212 llowing transplantation, 100% (14/14) of the surviving patients were able to discontinue parenteral t

213 8 year follow-up study was conducted wherein surviving patients were contacted by phone to evaluate s

214 Surviving patients were defined as those who were alive

215 Surviving patients were followed for a median of 62 mont

216 Surviving patients were followed up for 1 year after dis

217 fter treatment, and at last follow-up, all 6 surviving patients were free of blood product support an

218 es of death were "sudden" or "unknown." Most surviving patients were gainfully employed or attending

219 1.1% for transfemoral patients, and 73.5% of surviving patients were in New York Heart Association (N

220 At follow-up, 90% of surviving patients were in NYHA functional class I or II

221 Surviving patients were observed for a median of 8.4 yea

222 Blood samples from surviving patients were obtained and human leukocyte ant

223 Surviving patients were recruited for clinical and genet

224 Over 94% of surviving patients were reinterviewed about their axis I

225 The 39 surviving patients were rescanned one year following sur

226 Subsequently, surviving patients who consented were observed for 2 add

227 Surviving patients who crossed over to device treatment

228 Day-100 cytogenetics were evaluated in surviving patients who engrafted without infusion of unm

229 ned at scheduled times of evaluation for all surviving patients who have not withdrawn consent.

230 The surviving patients who received endovascular grafts had

231 8 (95% CI, 0.43-0.53), and the proportion of surviving patients who remained on dialysis was 0.10 (95

232 We recruited consecutive surviving patients who were English speaking, consented

233 years following the study year, only 52% of surviving patients who were initially prescribed lipid-l

234 r) have evidence of HCV infection, whereas 4 surviving patients who were transfused after March 1992

235 Among our surviving patients who were transfused between 1961 and

236 s, fungal or otherwise, were reported in the surviving patients, who ranged in age from 37 to 75 year

237 early-treated patients but in none of the 19 surviving patients with delayed treatment (P < .001).

238 The cohort of surviving patients with encephalitis was assessed for se

239 ibition prevents the clinical progression of surviving patients with heart failure more effectively t

240 sacubitril/valsartan leads to better HRQL in surviving patients with heart failure.

241 istribution of higher IgG antibody titers in surviving patients with HPS suggests that production of

242 In surviving patients with matched baseline and 12-month da

243 pitalization for congestive heart failure in surviving patients with matched data decreased from 0.59

244 rate the need for extended follow-up in long-surviving patients with oligometastatic disease.

245 ut have also resulted in a growing number of surviving patients with permanent structural damage of t

246 s of IFN- alpha were significantly higher in surviving patients with SEBOV infection, whereas the lev

247 fants, has a mortality of 30%, and can leave surviving patients with significant morbidity.

248 For 100 surviving patients with systemic vasculitis, the median

249 4) and 83% of upper-arm AVFs (341 of 411) in surviving patients without thrombosis or AVF interventio

250 Among surviving patients without thrombosis or AVF interventio